Best Free GLP-1 Samples in 2026

The federal sampling rule that breaks the obvious model

The Prescription Drug Marketing Act (21 U.S.C. § 353(d)) prohibits pharmaceutical manufacturers from distributing branded prescription samples directly to patients. Samples flow only to licensed prescribers, who allocate them to patients at their discretion. That single rule explains why the search query “free Ozempic samples” has no manufacturer-facing answer: there is no patient request form, no online sample signup, and no first-pen giveaway. What you see advertised as “free Ozempic” by anyone other than a state-licensed clinician is, by definition, not Ozempic — it's either a savings-card lead-gen, a compounded alternative, or marketing slop.

Manufacturer savings cards: the real consumer access program

Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) each run copay assistance programs that function as the consumer equivalent of a sample. For commercially insured patients whose plan covers the drug, the cards drop monthly cost to $0–$25. The mechanism: the manufacturer pays down a portion of the patient's insurer-defined copay, up to an annual cap. Federal-plan enrollees — Medicare, Medicaid, VA, Tricare — are excluded by federal anti-kickback statute. Most commercial plans in 2026 do cover Ozempic for diabetes; coverage of Wegovy and Zepbound for weight management is more variable and often requires prior authorization.

Telehealth as the prior-authorization workhorse

The hardest part of getting a branded GLP-1 in 2026 is rarely affording it once insurance is involved — it's clearing the prior authorization that most insurers require. Specialized telehealth providers (Ro, Found, WeightWatchers Clinic, LifeMD) have built dedicated PA teams that know the language each major insurer wants. Approval cycles that take 4–6 weeks at a typical primary-care office routinely close in 3–10 business days through these channels. The trade-off is a recurring membership fee, typically $99–$295 per month, that wraps the consult, the prior auth work, and clinical follow-up.

Compounded GLP-1: the closest thing to a real sample at scale

Compounded semaglutide and tirzepatide programs are typically the cheapest legitimate path for cash-pay patients. Reputable providers — Henry Meds, Mochi Health, Eden — work with state-licensed 503A pharmacies or 503B outsourcing facilities and charge $179–$249 for month one and $249–$349 ongoing. The drug is the same active ingredient as Ozempic or Mounjaro, prepared at a pharmacy-determined concentration against an individual prescription. The legal landscape changed when the FDA declared semaglutide off the shortage list in early 2025; tirzepatide had a similar declaration in late 2024. Compounded supply remains real but is now narrower than it was during the shortage windows.

We built this page for people typing “free GLP-1 samples” into Google in 2026 and getting a wall of programs that all promise the same thing. The honest filter: if you have commercial insurance, your real path is the manufacturer savings card plus a telehealth provider who can clear the prior authorization. If you're cash-pay and cost-sensitive, your real path is a compounded program from a state-licensed pharmacy. If you have Medicare, Medicaid, or another federal plan, neither manufacturer card is legally available to you, but Medicare Part D coverage of Ozempic for diabetes is reasonably reliable, and the diabetes-indication path is the one to push.

This page is not for people looking to skip a clinician. Every provider we recommend involves a board-certified clinician's judgment, and every prescription requires a documented diagnosis. Programs that promise GLP-1 access with no clinician involvement are not on this list, and they are rarely operating legally.